AP NEWS
This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: BusinessWire
This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.

BRAFV600 Mutation Inhibiotors - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 22, 2019

DUBLIN--(BUSINESS WIRE)--Jan 22, 2019--The “BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors

The report assesses the active BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors pipeline products by developmental stage, product type, molecule type, and administration route.

Topics Covered

1. Report Introduction

2. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors Pipeline Products in Clinical Stages

6. BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment - Active Products

8. Inactive Pipeline Products

Companies Featured

Plexxikon BeiGene Deciphera Pharmaceuticals Eli Lilly Pfizer Takeda Novartis Pharmaceuticals Corporation GlaxoSmithKline Roche Celldex Therapeutics Inc Ambit Biosciences Corporation Cephalon

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9g4qvv/brafv600_mutation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005422/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/22/2019 05:30 AM/DISC: 01/22/2019 05:30 AM

http://www.businesswire.com/news/home/20190122005422/en